INHALE-1: A 26-week Primary Treatment Phase with 26-week Extension Open-label Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections Both in Combination with a Basal Insulin in Pediatric

Go Back to All Clinical Trials

INHALE-1: A 26-week Primary Treatment Phase with 26-week Extension Open-label Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections Both in Combination with a Basal Insulin in Pediatric

Brief description of study

The purpose of this study is to find out whether an inhaled, ultra-rapid-acting insulin (Afrezza) works as well as rapid-acting injections. The possible benefits of Afrezza are that it works very fast and lasts for less time than injected insulin. That means you can take it with your first bite of food and there is less of a chance for having low blood sugar between meals. The Afrezza inhaler is small and does not require cleaning. It is small enough to hold in your hand and is easy to use.

Clinical Study Identifier: s22-00359

ClinicalTrials.gov Identifier: NCT04974528

Principal Investigator: Mary Patricia Gallagher.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies